Chris Moyes

Title: Innovations in Insulin Delivery by Chris Moyes

Introduction

Chris Moyes is an accomplished inventor based in Westfield, NJ (US), known for his significant contributions to the field of controlled insulin delivery systems. With a total of six patents to his name, Moyes has been at the forefront of developing innovative solutions that enhance the efficacy of insulin administration.

Latest Patents

Moyes' latest patents focus on conjugate-based systems for controlled insulin delivery. One of his notable inventions provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands, each including a saccharide. This innovative framework may also include a fatty chain, such as a C8-30 fatty chain. The conjugates are designed to exhibit pharmacokinetic (PK) and pharmacodynamic (PD) properties that are sensitive to serum concentrations of a second saccharide. Additionally, these conjugates are characterized by a protracted PK profile, which is crucial for sustained insulin release. Another patent further explores conjugates that include a first saccharide and a fatty chain, emphasizing the importance of these components in enhancing insulin delivery.

Career Highlights

Chris Moyes has made significant strides in his career, particularly through his work at Merck Sharp & Dohme Corporation. His innovative research and development efforts have positioned him as a key player in the pharmaceutical industry, particularly in the area of diabetes management.

Collaborations

Moyes has collaborated with notable colleagues, including Richard Berger and Lehua Chang, to advance his research and develop groundbreaking solutions in insulin delivery.

Conclusion

Chris Moyes continues to push the boundaries of innovation in insulin delivery systems, making a lasting impact on diabetes treatment. His work exemplifies the importance of research and collaboration in developing effective medical solutions.